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The antibody response magnitude and kinetics may impact clinical severity, serological
diagnosis and long-term protection of COVID-19, which may play a role in why children
experience lower morbidity. We therefore tested samples from 122 children in Hong Kong
with symptomatic (n = 78) and asymptomatic (n = 44) SARS-CoV-2 infections up to
200 days post infection, relative to 71 infected adults (symptomatic n = 61, and asymptomatic n = 10), and negative controls (n = 48). We assessed serum IgG antibodies to a 14wide antigen panel of structural and accessory proteins by Luciferase Immuno-Precipitation
System (LIPS) assay and circulating cytokines. Infected children have lower levels of Spike,
Membrane, ORF3a, ORF7a, ORF7b antibodies, comparable ORF8 and elevated E-speciﬁc
antibodies than adults. Combination of two unique antibody targets, ORF3d and ORF8, can
accurately discriminate SARS-CoV-2 infection in children. Principal component analysis
reveals distinct pediatric serological signatures, and the highest contribution to variance from
adults are antibody responses to non-structural proteins ORF3d, NSP1, ORF3a and ORF8.
From a diverse panel of cytokines that can modulate immune priming and relative inﬂammation, IL-8, MCP-1 and IL-6 correlate with the magnitude of pediatric antibody speciﬁcity
and severity. Antibodies to SARS-CoV-2 internal proteins may become an important sero
surveillance tool of infection with the roll-out of vaccines in the pediatric population.
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he spectrum of SARS-CoV-2 infection ranges from
asymptomatic to lethal infection, with the immune
response playing a major role in the pathogenicity
and outcome of COVID-191. Children are generally less affected
clinically by SARS-CoV-2 infection and the morbidity and
mortality observed in adults increases progressively with age. The
viral loads in the upper respiratory tract are reportedly comparable between children of all ages and adults2. Various immune
functions and physiological differences have also been implicated
in differential outcomes with age, such as lower ACE2 expression
in children3, pre-existing immunity to common cold coronaviruses (CCoV)4, elevated baseline IgM5, immuno-senescence,
inﬂammatory state6, innate immune responses7, auto-antibodies8,
and off-target “trained immunity”9,10. Multisystem inﬂammatory
syndrome (MIS-C) that can develop in children after infection
with SARS-CoV-2 is a rare exception (0.002% of pediatric cases)
to the generally milder clinical disease observed11.
Serology is crucial for determining infection attack rates in the
population and for assessing the response to current vaccines to
curb the global pandemic. Large epidemiological studies reported
that children only represent 1–2% of all SARS-CoV-2 cases in
202012,13. Most serological tests available rely either on neutralizing antibodies or on the detection of binding antibodies
targeting the Spike (S) or the Nucleocapsid (N) proteins of the
virus14. Across three commercial diagnostics S-based assays,
children show a lower rate of seroconversion than adults despite
having PCR conﬁrmed infection and comparable viral loads15,
therefore S-based serology in children may not be an accurate
marker of recent infection and underestimate seroprevalence in
children. Furthermore, N-speciﬁc antibody waning is more pronounced than S16 and children are more likely to test S-antibody
positive even in the absence of vaccination17. Therefore, N-based
serology in children is also limited18 compared to adults19. Salivabased approaches may offer an easier sampling site with longterm duration of IgG and N-speciﬁc responses20,21 over S22 and
IgA, even in children23.
We have previously demonstrated that antibodies that are
directed against non-structural proteins of the virus, namely
ORF3d and ORF8, can be used for accurate diagnosis of SARSCoV-2 infection in adults24. Further studies have also contributed
data on the SARS-CoV-2 antibody responses to the virus accessory proteins in the adult population24–26 but these accessory
speciﬁc antibody data are lacking for children. For instance,
ORF3d, ORF6, and ORF7a, which have been reported to be
potent interferon antagonists that may play a role in immune
evasion27–29, or ORF8, which seems to participate to the downregulation of MHC I molecules and to viral pathogenesis30,31. In
addition, an imbalanced production of cytokines is responsible of
severe COVID-19 outcomes in adults32 which may modulate
seropositivity. Finely tuned and balanced antibody response in
relation to cytokine responses may impact SARS-CoV-2 infection outcomes, thus the breadth and magnitude of the speciﬁcity
of antibody responses to non-structural proteins may indicate the
extent of virus replication and thus immune control.
In the present study, children and adults with SARS-CoV-2
RT-PCR conﬁrmed infection were used to determine the antibody speciﬁcity to a comprehensive panel of 14 different
structural and accessory proteins by Luciferase ImmunoPrecipitation System (LIPS) (l). Antibody responses were then
compared relative to circulating levels of a selected panel of
cytokines, known to modulate the antibody response and
inﬂammation. The majority of samples were collected between
April to November 2020, before the roll-out of COVID-19
vaccines. Furthermore, due to intensive contact tracing and
case-ﬁnding measures in Hong Kong, asymptomatic pediatric
cases with RT-PCR conﬁrmed infections have been included,
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which represents a rare entity in most countries and are a
unique aspect of our study.
Results
Different levels of antibodies to structural proteins in children
and adults with SARS-CoV-2 infection. We used the unbiased
and quantitative LIPS platform to determine the antibody
responses to an extensive panel of 14 antigens from structural and
non-structural SARS-CoV-2 proteins in plasma samples from a
cohort of infected children, in comparison to adults and controls
in Hong Kong and the USA (Table 1).
Our ﬁrst dataset represents the total cohort of SARS-CoV-2
infected cases of mixed time points and symptoms to determine the
overall antibody speciﬁcity in children (mean ± stdev: 39 ± 47 days,
range: 0–206 days), adults (mean ± stdev: 20 ± 23 days, range: 0-123
days) and negative controls (Table 1: adults with asymptomatic,
mild, or severe disease, children with asymptomatic or mild disease,
and negative controls). S and N antibodies are the most widely used
antibodies in COVID-19 serology testing worldwide. We therefore
ﬁrst determined the levels of antibodies to different S sub-units by
using 3 different S constructs in the LIPS assay: S1 which contains
the RBD domain, S2, and the S2′ cleaved subunit (Fig. 1). The levels
of the two Spike antibodies, S1 and S2′ were markedly lower in
children compared to the adult cohort (both p < 0.0001, Fig. 1a, c),
whereas no difference was observed for S2 antibodies, revealing
different antigenicity for the two Spike isoforms S2 and S2′
(Fig. 1b)33. Moreover, N antibodies were signiﬁcantly elevated in
the pediatric COVID-19 cohort relative to negative controls
(2.45 × 105 ± 2.8 × 105 LU
versus
4.15 × 104 ± 1.5 × 105 LU
(p = 0.0045), but did not differ from levels observed in adults
(Fig. 1d).
We also assessed by LIPS antibodies to other structural
proteins Matrix (M) and Envelope (E), which are not widely
measured in serology. As for S1 and S2′, we found that M
antibody levels were lower in infected children compared to
infected adults (p < 0.0001, Fig. 1e), but were still signiﬁcantly
higher than negative controls. E antibodies had an opposite effect,
and were signiﬁcantly elevated in the pediatric COVID-19 cohort
(Fig. 1f) compared to both adult COVID-19 (p = 0.0006) and
negative controls (p < 0.0001). This antigen panel revealed that N
and E were the best-performing antigens for diagnostics (based
on a cut-off of the negative mean + 3x standard deviations) in the
pediatrics population with 65% sensitivity and 100% speciﬁcity
for N and 78% sensitivity and 100% speciﬁcity for E (Fig. 1d, f),
which contrasts to our previous analysis in an adult population
where E was not immunogenic24.
Increased antibody response to the accessory protein ORF8 in
the pediatric SARS-CoV-2 infected population. We next
investigated the levels of antibodies directed against the nonstructural protein 1 (NSP1) and all the ORF proteins of the virus.
In line with our previous study24, infected adults had elevated
levels of NSP1, ORF3a, ORF3d, ORF7a, ORF7b, and ORF8 antibodies compared to negative controls (p < 0.0001, p < 0.0001,
p < 0.0001, p = 0.05, p = 0.0009, p < 0.0001, Fig. 2a–c and e–g). No
detectable levels of ORF6 and ORF10 antibodies were found in
infected adults (p = 0.8691 and p = 0.999, respectively, Fig. 2d, h).
We observed that the COVID-19 children cohort displayed signiﬁcantly lower levels of ORF3a, ORF7a, ORF7b antibodies than
the COVID-19 adult cohort (p = 0.0001, p < 0.0001 and
p < 0.0001, respectively, Fig. 2b, e, f). The magnitude of antibody
responses to NSP1 and ORF3d (previously referred to as ORF3b24,
as ORF3d is within frame of ORF3b but ORF3b is not
expressed34) were comparable in the pediatric COVID-19 and
adult COVID-19 populations (Fig. 2a, c).
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–
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Mean ± stdev
Adults (N = 28)
Pediatrics (N = 20)

N (%)

71
71
10 (14%)
50 (70.5%)
11 (15.5%)
Mean ± stdev
Median
Min
Max
34 (48%)
37 (52%)

N (%)

254
122
44 (36%)
78 (64%)
0
Mean±stdev
0–8 years
8–12 years
12–18 years
49 (40%)
73 (60%)
Female
Male
Sex

Age

Symptoms

Samples
Individuals
Asymptomatic
Mild
Severe
Patients

Table 1 Subject cohorts details.

10.8 ± 4.9 years
45 (37%)
33 (27%)
44 (36%)

Adult COVID-19
Pediatric COVID-19

43.7 ± 19.3 years
45
18
84

48
48
–
–

N (%)

Negative

–
18–65
11–18
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ORF8 antibody levels were found signiﬁcantly elevated in
pediatric COVID-19 samples compared to adults (p < 0.0001,
Fig. 2g). In terms of performance as a diagnostic test, ORF8
antibodies by LIPS allows for the detection of nearly all the
pediatric population with a sensitivity of 99.2% and speciﬁcity of
100% (Fig. 2g). These results were then conﬁrmed in an in-house
ELISA assay for IgG binding using recombinant proteins in both
adult and pediatric plasma samples, where ORF8-protein35
binding antibodies showed 79% sensitivity and 98.4% speciﬁcity
(Supplementary Fig. 1c), whereas N and Spike-protein binding
antibodies showed a sensitivity of 88% and 11% and a speciﬁcity
of 97% and 99%, respectively (Supplementary Fig. 1d, e).
Furthermore, ORF8 remains a speciﬁc diagnostic tool for
SARS-CoV-2 infection in vaccinated conditions. ORF8 speciﬁc
IgG was assessed following vaccination with whole inactivated
virion Coronavac and Spike mRNA lipoprotein BNT162b2
(Supplementary Fig. 1f), showing ORF8 is likely not incorporated
within the virion.
We then compared the cumulative SARS-CoV-2 antibody
responses from asymptomatic/mild only COVID-19 children
and adult in a heatmap (Fig. 2i) and as percentages of the total
SARS-CoV-2 structural and accessory antibody response
(Fig. 2j). Due to the immunodominant effect of the N protein,
anti-N antibodies substantially dominate the SARS-CoV-2
humoral response detected by LIPS in both populations
(Fig. 2i), which is consistent with our previous ﬁndings in
the adult population24. There was a signiﬁcant difference in the
distribution of the overall speciﬁcity of pediatrics and
asymptomatic/mild COVID-19 adults (p < 0.0001 for
“observed” pediatric distribution compared with “expected”
adult distribution, Fig. 2j, Supplementary Fig. 1a, Supplementary Table 3). In the adult population antibody levels of S1, M,
ORF3a and ORF7b represented a higher percentage of the
response in adults than children (Fig. 2j and Supplementary
Fig. 1a). While, ORF8 and E antibody responses represented a
higher percentage in the pediatric population with 13.4%
versus 9.2% and 11% versus 4.8%, respectively (Fig. 2j and
Supplementary Fig. 1a). The remaining antigens, S2, S2′, N,
NSP1, ORF3d, ORF6, ORF7a, ORF10, represent a similar
percentage in both populations and hence are not contributing
to the differences observed in speciﬁcity. Furthermore,
there are no differences in total IgG serum concentration with
age or infection, despite differences in the magnitude and
speciﬁcity of SARS-CoV-2 antibodies in adults versus children
(Supplementary Fig. 1b).
SARS-CoV-2 antibody speciﬁcity using clusters of points and
principal component analysis. A cluster of points depicts each
individual sample in a more complete way than a classical single
statistical comparison, as it considers a combination of three (or
more) different parameters taken together and the relevant relations of these parameters. To decipher the SARS-CoV-2 antibody
speciﬁcity in children, we used relevant antibody combinations to
represent the COVID-19 pediatric samples in clusters of points
relative to negative controls and COVID-19 adult populations
(Fig. 3a–c and Supplementary Fig. 2).
First, the cluster representing the three antibodies to the S subunit
antigens S1, S2′, S2 conﬁrmed that the pediatric population has a S
antibody proﬁle that is more closely comparable to negative controls
(Fig. 3a) than an adult COVID-19 response by LIPS (Fig. 3b).
Further cluster analysis of antibodies to other structural proteins N,
M, and E reveals that the COVID-19 children population appears to
be quite heterogeneous with a large range in response magnitude
compared to adults (Supplementary Fig. 2b, c). Despite having a
different proﬁle than both the adult COVID-19 and the negative
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Fig. 1 Comparison of antibody responses to SARS-CoV-2 structural proteins in children and in adults with COVID-19. Antibodies against the SARSCoV-2 structural proteins Spike S1 subunit (S1) (a), Spike S2 subunit (b), Spike S2′ subunit (c), Nucleocapsid (N) (d), Membrane (M) (e), and Envelope (E)
(f) were measured by LIPS from samples from pediatrics COVID-19 (n = 254) or adult patients (n = 71), and negative controls (n = 48). Background no
plasma values were subtracted. Experiments were repeated twice. The cutoff value is shown by the dotted line and was based on the mean plus 3 × s.d. of
the negative control group. All data represent individual time point IgG responses and to a lesser extent IgA and IgM based on protein A/G bead binding by
LIPS and the mean ± stdev. Two-sided P values were calculated using the Mann–Whitney U test. * shows statistical signiﬁcance between COVID-19
patients versus negative controls. **p < 0.01, ***p < 0.001, ****p < 0.0001. Signiﬁcant p values for pediatrics versus adults are S1 (a) p < 0.0001, S2′ (c)
p < 0.0001, M (e) p < 0.0001, E (f) p < 0.0001. Signiﬁcant p values for pediatrics versus negatives are N (d) p < 0.0001, M (e) p = 0.0008, E (f)
p < 0.0001.

populations, the infected pediatric population cannot be clearly
discriminated from these two groups using antibodies to structural
proteins.
We then selected accessory protein antibodies as combinations
to investigate the relevance of unique markers. Previously we
showed that, ORF3d, ORF8, and N antibodies, can discriminate
accurately COVID-19 adults from negative controls24. The (N,
ORF3d, ORF8) cluster of points can accurately allow the positive
discrimination of the pediatric COVID-19 cases from the negatives
(Fig. 3c). In the (N, ORF8; x, y) plane, the negative population is
separated from the pediatric positive one by two-segments of
straight lines (equations of 830*log (N) + 0.3843*ORF8 = 4801
and −350*log (N) + 1.036*ORF8 = 790), with all pediatric
positive samples (red dots) represented above or on these lines,
and only one negative sample (gray triangle) being above these
lines (speciﬁcity of 96.9% and sensitivity of 100% for pediatric
cases). Of note, this plane did not allow an accurate discrimination
of the adult positive population (blue dots) with the negative one
(gray triangles), as some adult samples (n = 8 of 71) were found
below these lines, with the negatives. Interestingly, these 8 samples
were early time-point samples (mean time-point sampling: 2.6 days
of infection).
Furthermore, the plane (ORF8, ORF3d; y, z) and a two-segment
delineation (equations of 0.035*ORF3d + 0.1334*ORF8 = 409.284
and 0.074*ORF3d + 0.0437*ORF8 = 221.812) separated the
4

negative samples from all the adult and pediatric positive ones
(100% sensitivity and 100% speciﬁcity), therefore the combined use
of ORF3d and ORF8 most accurately discriminates infected
samples from uninfected controls. While the combination of
ORF3d and N did not allow any clear discrimination of any of the 3
populations: pediatrics infected, adults infected, and negatives.
Therefore, using the (N, ORF3d, ORF8) cluster analysis, the
pediatric COVID-19 population resembles a COVID-19 adult
population when these markers are taken together only, and can
be discriminated from negative pre-pandemic controls. Importantly, this is the only combination that allowed us this
discrimination of infected samples, as other parameter combinations (e.g., (S1, S2, S2′) in Fig. 3, (N, E, M) in Supplementary
Fig. 2) and combinations of antibodies to accessory proteins)
were also tested and represented as clusters of points but did not
discriminate pediatric samples. Our combined antigen analysis
(Fig. 2i) and these various data cluster analyses show that the
antibody speciﬁcity of the COVID-19 children population is
distinct from infected adults.
To test the hypothesis that the antibody speciﬁcity to structural
and accessory viral proteins drives the distinct proﬁle of the
pediatric population, we undertook a principal-component
analysis (PCA) of antibodies to the 14 SARS-CoV-2 antigens
for the full dataset (from Figs. 1 and 2). Dimension (principal
component) 1 and 2 explained, respectively, 20.6% and 17.7% of
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Fig. 2 Diverse distribution of antibody responses to single SARS-CoV-2 proteins in children and adults with asymptomatic/mild COVID-19.
a–h Antibody levels to accessory proteins of SARS-CoV-2. Antibodies against NSP1 (a) (in ORF1ab), and other ORFs (ORF3a (b), ORF3d (c), ORF6 (d),
ORF7a (e), ORF7b (f), ORF8 (g), and ORF10 (h)) were measured in pediatric (n = 254) and adult (n = 71) COVID-19 cases and negative controls (n = 48)
by LIPS to cover all the ORFs of the virus. Signiﬁcant p values for pediatrics versus adults are NSP1 (a) p = 0.0005, ORF3d (b) p < 0.0001, ORF7a
p < 0.0001, ORF7b p < 0.0001, ORF8 p < 0.0001. Signiﬁcant p values for pediatrics versus negatives are NSP1 (a) p < 0.0001, ORF3d (b) p < 0.0001, ORF7a
p < 0.0001, ORF8 p < 0.0001, ORF10 p < 0.025. i, j Comparison of the antibody distribution in asymptomatic/mild children and adults. The cutoff value is
shown by the dotted line and was based on the mean plus 3 × s.d. of the negative control group. i Heatmap comparing the mean concentrations (LU) for
structural (N, S, S1, S2′, S2, M, E) and accessory proteins (NSP1, ORF3a, ORF3d, ORF6, ORF7a, ORF7b, ORF10) responses in the COVID-19 pediatric,
asymptomatic/mild adult populations (excluding severe cases) and negative controls. j Percentages of single antibody levels to SARS-CoV-2 antigens of
the cumulative SARS-CoV-2 antibody response in COVID-19 children and asymptomatic/mild adults (excluding severe cases) for the antigen panel
including and excluding N. The asymptomatic/mild pediatric and adult distributions were compared using a Chi-square test for expected versus observed
distributions. Expected (adult) and observed (pediatric) percentages are detailed in Supplementary Table 3. P < 0.0001 for pediatric (observed) versus
adult (expected) distribution of both antigen panels including N (left) and excluding N (right). Experiments were repeated twice. Two-sided P values were
calculated using the Mann–Whitney U test. * shows statistical signiﬁcance between COVID-19 patients versus negative controls. *p < 0.05, **p < 0.01,
***p < 0.005, ****p < 0.0001. Data in (a–h) represents individual time point LIPS responses and the mean ± stdev, data in (i) represents mean values (LU),
data in (j) represents percentages.

the total variances from all the 14 antibody types (Supplementary
Fig. 3 and Fig. 3d, e). Antibodies to accessory proteins ORF3d,
NSP1, ORF3a, ORF8, ORF7a had high correlation values
(Supplementary Table 2), reﬂecting that antibodies to structural
proteins do not solely drive the principal component 1.
Particularly, contributions of ORF3d, NSP1, ORF3a, ORF8 were
the highest in Dimension 1 (Dim1, Fig. 3d, e and Supplementary
Table 3). Moreover, PCA showed that ORF3d and ORF7a
antibodies highly contributed to the differences seen in both
dimensions (Fig. 3e, f) highlighting their discrimination in the
serological response.
Strikingly, the PCA revealed that pediatric COVID-19 antibody
response was also intermediate between COVID-19 adults and
negatives (Fig. 3g). Indeed, the normal-probability representation
of the 3 populations showed that only 31.5% of the pediatric
patients overlapped with the ellipse of the COVID-19 adults and

only 4.72% overlapped with the ellipse of negative controls (Fig. 3g).
Figure 3h and statistical comparison of the 2-dimensional
distributions of the pediatric and adult groups “asymptomatics”,
“mild”, and “severe” revealed that the distribution of the population
of severe adult patients was signiﬁcantly different than that of the
adult mild or asymptomatic populations (p = 0.027 for severe
versus asymptomatic adult cases, and p = 0.011 for severe versus
mild adult cases with the Kolmogorov–Smirnov test36,37. Overall,
the PCA showed that adults with severe symptoms had a distinct
PC value distribution than adults with mild symptoms (Fig. 3h),
which may be driven by these differences in S1, S2′, and ORF8.
Further analysis on sex, infection time-point, and neutralization data (PRNT90) values showed they were not signiﬁcant
factors in discriminating the antibody speciﬁcity data (Supplementary Fig. 3). Therefore, the differences in the observed SARSCoV-2 antibody responses are primarily explained by the age of
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M
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ORF3a
0.0
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8
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6

N

4

ORF8
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E
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−1.0

−0.5

0.0

0.5

1.0

Dim1 (20.6%)

Individuals − PCA
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5.0
5.0

2.5
2.5

Adults positives
Negatives
Pediatrics positives

Dim2 (17.8%)

Dim2 (17.8%)

Symptoms
Groups
0.0

Adults asymptomatic
Adults mild
Adults severe
Negatives

0.0

Pediatrics asymptomatic
Pediatrics mild

−2.5

−2.5

−5.0

−2.5

0.0

Dim1 (20.6%)

2.5

−5.0

−2.5

0.0

2.5

Dim1 (20.6%)

Fig. 3 Representation of the pediatric COVID-19 population as a cluster of points for relevant antibody combinations and principal component analysis
(PCA). a, b Cluster representation of S1, S2′, S2 antibodies combination. a The pediatric COVID-19 population versus the negative population, b the
pediatric COVID-19 population versus the adult COVID-19 population (for the sake of clarity, the three populations were not represented on the same
graph here). c Cluster representation of N, ORF3d, ORF8 antibodies combination, for the pediatric COVID-19 population versus the adult COVID-19
population and the negative population. Samples are represented according to their values of SARS-CoV-2 individual LIPS antibodies as (x, y, z) in the
space. For the sake of clarity, only n = 144 pediatric COVID-19 (red), n = 71 adult COVID-19 (blue), and n = 48 negative (gray) samples are represented
(a–c). d–f PCA of 14 antibodies analyzed in COVID-19 pediatric patients. Dim1 explains 20.6% of the variation, while Dim2 explains 17.7% of the variation.
d Contribution of variables on dimensions 1 and 2. The red dashed line on the graph above indicates the expected average contribution. e Correlation circle
and contributions. The scale of contributions is indicated (right). f Summary of contribution of variables on the different dimensions. g, h Factorial plots of
PCA on dimensions 1 and 2. The plot is colored by sample types (Adults positives, Pediatrics positives, negative controls) (g), the largest point in shape in
each group is the group mean point (circle is for Adult positives, squares for Pediatric positives, triangle for Negative controls) or by symptoms (h).

patients (pediatric COVID-19, adult COVID-19 or pre-pandemic
negative controls), and clinical symptoms.
No difference in antibody responses between symptomatic and
asymptomatic COVID-19. To assess the potential effect of
antibodies to structural and non-structural proteins of SARSCoV-2, we further stratiﬁed data (from Figs. 1 and 2) into
symptomatic (including mild (WHO score 1–3) and severe
(WHO score 4) and asymptomatic (WHO score 0) for both the
adult and pediatric cohorts (Fig. 4). We found no differences in
antibody responses between asymptomatic versus mild COVID19 children for all 14 antigens. The same trend was observed in
adults (Fig. 4a, b). More importantly M, NSP1, ORF6, ORF8, and
ORF10 antibody levels in asymptomatic children versus asymptomatic adults were not signiﬁcantly different (p = 0.3676,
p = 0.5216, p = 0.1276, p = 0.2775 and p = 0.0521, respectively,
Fig. 4), while symptomatic adults had an upregulated antibody
response to these antigens compared to symptomatic children
(p < 0.0001 for all antigens, except p = 0.0001 for NSP1, Fig. 4).
Antibody speciﬁcity at early infection and long-term stability.
We previously observed that the SARS-CoV-2 antibody responses
6

can vary in magnitude and speciﬁcity in adults between acute and
convalescent to memory time-points24. To study the effect of time
on the pediatric SARS-CoV-2 antibody speciﬁcity, we stratiﬁed
pediatric responses of all 254 samples (Figs. 1 and 2) by early
(<d14) versus later (≥d14) time-points of infection (Fig. 5). S2, N,
and ORF7a speciﬁc antibodies were signiﬁcantly increased after
day 14 post symptom onset. In contrast, ORF3d and ORF7b
antibodies elicited a higher antibody response prior to day 14
(Fig. 5b). Finally, responses to structural proteins S1, S2′, M, and
E and accessory proteins NSP1, ORF3a, ORF6, and ORF8 were
comparable before and after day 14 (Fig. 5a, b). Further stratiﬁcation of samples according to time-point of sampling and
symptoms was then performed (Fig. 5c) and showed signiﬁcant
differences for symptomatic pediatric patients for convalescent
samples for key antigens, S2, ORF3d, ORF7a, and ORF7b.
To further conﬁrm the stability of SARS-CoV-2 speciﬁc
antibodies, we used 146 longitudinal paired samples of 58
pediatric patients that had either 2, 3 or 4 blood draws (Fig. 6a).
The time frame of sampling ranged from 0 to 206 days postsymptom onset, with most samples from <14 days (n = 63), or
long-term memory samples after day 60 (n = 58) (Fig. 6B). Using
a linear mixed-effects model, we determined that antibody
responses to structural proteins S1, S2, S2′, M, and E were stable
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Fig. 4 Asymptomatic and mildly symptomatic children do not display different antibody responses. Pediatric and adult samples were stratiﬁed
according to the symptom score of the patients (asymptomatic “asympto” (pediatric COVID-19 n = 98, adults COVID-19 n = 10) versus symptomatic
“symptom” (pediatric COVID-19 n = 156, adults COVID n = 52)), data from Figs. 1 and 2 were analyzed according to “asympto” and “sympto”.
a Antibodies against the SARS-CoV-2 structural proteins S1, S2, S2′, N, E, and M by LIPS. Signiﬁcant p values for asympto pediatrics versus asympto adults
are S1 p = 0.0005, S2′ p = 0.0221, E p = 0.0071. Signiﬁcant p values for sympto pediatrics versus sympto adults are S1 p < 0.0001, S2′ p = 0.0016, M
p < 0.0001, E p < 0.0001. b Antibodies against SARS-CoV-2 NSP1 (in ORF1ab), and all other ORFs (ORF3a, ORF3d, ORF6, ORF7a, ORF7b, ORF8, and
ORF10). Signiﬁcant p values for asympto pediatrics versus asympto adults are ORF3d p < 0.0001, ORF7a p = 0.0358, ORF7b p = 0.0208. Signiﬁcant p
values for sympto pediatrics versus sympto adults are NSP1 p = 0.0001, ORF3d p < 0.0001, ORF6 p < 0.0001, ORF7a p < 0.0001, ORF7b p < 0.0001, ORF8
p < 0.0001, ORF10 p < 0.0001. Two-sided P values were calculated using the Mann–Whitney U test. * shows statistical signiﬁcance between COVID-19
patients versus negative controls. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0,0001. All data represents individual time point LIPS responses and
mean ± stdev.

over time, whereas N was signiﬁcantly increased (p < 0.001)
(Fig. 6c). Furthermore, antibodies towards non-structural proteins NSP1, ORF3a, ORF3d, and ORF7a also signiﬁcantly
increased over time (p < 0.001, p = 0.001, p = 0.027 and
p = 0.002, respectively), while ORF6, ORF8, and ORF10 were
stable (Fig. 6c). Only ORF7b antibody response signiﬁcantly
decayed longitudinally at a slow rate (equation of: log10
LIPS = 3.5539−0.0016 * day after onset, p < 0.001, Fig. 6c). To
determine whether the slope of each serological marker was
related to symptoms we compared asymptomatic and symptomatic patients, but no signiﬁcant differences were found (p > 0.05
for all) (Supplementary Fig. 4).
Effect of age within the pediatric population. Further stratiﬁcation of the pediatric cohort according to the age of the patients
was performed but did not reveal a speciﬁc pattern for any agegroups (0–2, >2–10, >11 years old) as shown by the representation of the population as a cluster of points for the most
relevant (N, ORF8, ORF3d) antibody combination (Supplementary Fig. 5).

Circulating cytokine levels. Severe COVID-19 has been linked
with a cytokine storm38 and some cytokines are now the targets
of COVID-19 therapies, i.e., IL-6 for which a monoclonal antibody therapy is being investigated for the treatment of critically ill
COVID-19 patients39. Because children mainly suffer from mild
COVID we sought to investigate the relationship between antibody production and cytokine proﬁle in this population. We
selected pro-Th1/Th2, pro/anti-inﬂammatory cytokines, and
chemokines that had also been described as early prognostic
markers of severe COVID-1940,41 and therefore play an important role in shaping the adaptive immune priming. Cytokines of
interest were quantiﬁed at acute stages of infection (<day 7 from
36 mild COVID-19 children and adults and 10 severe adults from
the total cohort were measured in the plasma samples with a
Cytokine Bead Array to determine the relationship between
inﬂammation and seroconversion. Levels of plasma chemokines
IL-8, CXCL10, and MCP-1 were signiﬁcantly elevated in mild
adults compared to pediatric cases (p = 0.0019, p = 0.078
and p < 0.0001, Fig. 7a). Of note, CXCL-10 levels were also found
signiﬁcantly elevated in severe adults versus mild adults and
versus pediatric cases (p = 0.0067 and p = 0.0025). The pediatric
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Fig. 5 Unique antibody speciﬁcities are characteristic of early time-point samples (< day 14). Pediatric samples were stratiﬁed according to the timepoint of collection, and data from Figs. 1 and 2 were analyzed according to acute (<day 14, n = 119) and later time-points (≥day 14, n = 135). a Antibodies
against the SARS-CoV-2 structural proteins S1, S2, S2′, N, E, and M by LIPS. Signiﬁcant p values for <day 14 versus ≥day 14 are S2 p = 0.0287, N
p < 0.0001. b Antibodies against NSP1 (in ORF1ab), and all other ORFs (ORF3a, ORF3d, ORF6, ORF7a, ORF7b, ORF8, and ORF10). Signiﬁcant p values for
<day 14 versus ≥day 14 are ORF3d p = 0.0001, ORF7a p = 0.048, ORF7b p = 0.0093, ORF10 p = 0.0288. Two-sided P values were calculated using the
student t test. * shows statistical signiﬁcance between acute time-point pediatric COVID-19 patients versus late time-point pediatric COVID-19 patients.
c Stratiﬁcation of S2, ORF3d, ORF7a, and ORF7b antibody levels measured by LIPS according to symptoms (“asympto” for asymptomatic, “sympto” for
symptomatic) and time-point of sampling (prior day 14 or after day 14). Signiﬁcant p values for <day 14 asympto versus <d14 sympto are S2 p = 0.0172.
Signiﬁcant p values for asympto <d14 versus asympto >d14 are ORF3d p = 0.0309. Signiﬁcant p values for sympto <d14 versus sympto >d14 are S2
p = 0.0021, ORF3d p = 0.0044, ORF7a p = 0.0066, and ORF7b p = 0.0123. Two-sided P values were calculated using the Mann–Whitney U test. * shows
statistical signiﬁcance between symptomatic and asymptomatic samples or between early and late samples *p < 0.05, **p < 0.01, ***p < 0.005,
****p < 0.0001. All data represents individual LIPS responses and mean ± stdev.

population also showed reduced levels of the pro-inﬂammatory
cytokine IL-6 with a 3-times reduction versus adult mild cases
(mean ± stdev: 13.86 ± 27.7 versus 41.21 ± 57.1, p = 0.0394).
To evaluate the importance of each of the cytokines and
antibody speciﬁcity, we performed a PCA of the cytokine levels
and antibody responses and found that IL-8 and MCP-1 were the
biggest contributors to the overall antibody responses in Dim.1
and Dim.2 (p < 0.05) (Fig. 7b). Moreover, IL-6, TGF-β1, CXCL10, and IL-4 all correlate with Dim.1, with IL-4 being the only
cytokine correlating negatively (Fig. 7b). Our focus was then
brought to the correlation of each speciﬁc antigen with the
cytokines of interest IL-8, MCP-1, IL-6, and TGF-β1 (Fig. 7c).
Amongst structural proteins, responses to S1 and E correlated
negatively with IL-8 responses, while M correlated positively with
8

these cytokines (Fig. 7c, p < 0.0001, p < 0.001 and p < 0.001,
respectively). Furthermore, antibodies to accessory proteins
NSP1, ORF3a, ORF3d, and ORF8 positively correlated with IL8 responses (Fig. 7c, p < 0.05, p < 0.05, p < 0.05 and p < 0.0001,
respectively). ORF3d and ORF8 responses also correlated
positively with MCP-1 levels (Fig. 7c, p < 0.05). On the other
hand, antibodies to the structural protein E correlated negatively
with all four cytokines of interest (p < 0.0001 for IL-8, MCP-1,
and IL-6, and p < 0.05 for TGF-β1). Importantly, E antibodies
were elevated in infected children (Fig. 1f).
Furthermore, a positive correlation was found between N,
NSP1, and ORF3a antibody responses and IL-6 (Fig. 7c, p < 0.05).
Finally, we analyzed if a pattern related to these cytokines could
predict disease outcome, and found that IL-6 and IL-8 levels were
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Fig. 6 Longitudinal stability of antibody responses for structural and non-structural SARS-CoV-2 proteins in COVID-19 children. a Number of
longitudinal patients with either 2, 3, or 4 blood draws from 58 pediatric COVID-19 cases. b Sample collection time-line (days post infection). For each plot,
whiskers are minima to maxima, and center is mean, no percentile is shown. Detailed minima, maxima, mean ± S.D. are as follows: Days 0–14:0, 14,
7.4 ± 4.02, days 15–28: 15, 19, 17.0 ± 1.51, days 29–60: 30, 60, 48.7 ± 9.78, days 61–120: 62, 119, 91.7 ± 15.42, days 121–180: 122, 179, 156.3 ± 19.96, days
181–240: 181, 206, 192.7 ± 11.33. c A linear trend on log10 LIPS values was ﬁtted for longitudinal samples for S1, S2′, N, M E, NSP1, ORF3a, ORF3d, ORF7a,
ORF7b, ORF8 (n = 58 pediatric COVID-19 patients). Linear mixed-effects models were ﬁtted to test the trend of the antibody responses. The trend is
speciﬁc to each SARS-CoV-2 protein and hence adjustment for multiple comparisons is not needed.

strongly associated in Dim1 with disease severity (p < 0.05 and
p < 0.0001, respectively, Fig. 7d). This highlights the close
correlation of antibody responses toward the driving antibodies
of Dim.1 (ORF3d, NSP1, ORF8, and ORF3a) and cytokine
responses (particularly for IL-6 and IL-8) with disease outcome.
Discussion
Young children account for only a small percentage of reported
and medically attended COVID-19 infections9. This difference is
likely contributed to by differences in host responses between
children and adults that ultimately drive adaptive immunity. We
present herein a comprehensive study of the magnitude, speciﬁcity, and duration of SARS-CoV-2 speciﬁc antibodies in children.

Our data show that children produce antibodies to some
accessory proteins at reduced levels compared to adults (namely
S1, M, ORF3a, ORF7b), and that only one accessory target
induced an increased antibody response: ORF8. Overall, we found
a signiﬁcant diverse distribution of the antigenic targets in children and adults. These diverse levels of antibodies to structural
and accessory ORF proteins may reﬂect different virus pathogenesis in children compared to adults. Viral loads have been
shown to be comparable in children and adults, which may reﬂect
similar levels of viral replication2. The higher levels of ORF8
antibodies in the pediatric population could be of particular
interest as this glycoprotein has been shown to downregulate
MHC-I molecules30 and seems to play an important role in viral
pathogenesis31. Similarly, we also observed that severe adult cases
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Fig. 7 IL-8 and MCP-1 contribute the biggest determinate of the COVID-19 antibody responses, and IL-6 and IL-8 are associated with disease severity
of antibody responses. a Plasma levels of 13 circulating cytokines in pg/mL for acute samples (<day 7) for pediatric cases (n = 35) or adults mild (n = 34)
and severe cases (n = 10): IL-2, IL-12p70, IL-4, IL-1β, IL-6, IFN-γ, IL-17A, TNF-α, IL-10, TGF-β1, IL-8, CXCL-10, MCP-1. Data represent individual cytokine
responses and mean ± stdev. For pediatrics versus adults mild: p = 0.0019 for IL-8, p = 0.0078 for CXCL10, p < 0.0001 for MCP-1. b Highest correlation
coefﬁcient of cytokines with Dim-1 and Dim-2 of the antibody responses from Fig. 3. c Correlation coefﬁcients of speciﬁc antigens with the cytokines of
interest IL-8, MCP-1, IL-6, and TGF-β. d Association of IL-6 and IL-8 levels with clinical symptoms in Dim-1 and Dim-2 of the antibody responses from
Fig. 3. Severe (triangles) and mild (square) cases are darker than asymptomatic cases and located on the right of the graph meaning that they strongly
associated with Dim-1 ((p < 0.05 and p < 0.0001, respectively). Data were analyzed using the two-sample Wilcoxon test for comparison of the responses
between asymptomatic and symptomatic cases.

had lower levels of ORF8 antibodies than mild adult cases, and
that infected children had elevated ORF8 antibodies, therefore
ORF8 antibodies may function as a positive immune correlate.
Whether ORF8 antibodies found in children can block some of
the deleterious functions of this protein remains to be determined
by functional studies. Higher ORF8 antibodies in children is also
in line with reduced cellular immunity42, and may also reﬂect
higher expression of ORF8 during pediatric infection that is
known to reduce MHC-I presentation30.
Antibodies to the structural protein E were also present in
higher proportions in children than adults, and the E protein is
notorious for high turnover due to its pivotal role in viral propagation (reviewed in ref. 43). Therefore the extent and speed of
virus replication in pediatric cells may be different to adults due
to differences in innate pathway activation44 leading to antibody
priming being elevated in children for E, which warrants further
investigation.
For the antibodies to Spike sub-units, the (S1, S2′, S2) cluster
reveals that the children population resembles a negative prepandemic population and not a COVID-19 adult one. A recent
study describes a lower anti-S IgG, IgM, IgA in the pediatric
population which correlates with our ﬁndings45. One explanation
for the clinical difference between children and adults is that the
pre-existing immunity against seasonal human CCoV that crossreacts with SARS-CoV-2 is higher in children, as they have a
10

higher infection rate of seasonal CCoV than adults46. Individuals
exposed and unexposed to SARS-CoV-2 have cross-reactive
antibodies against the proteins of SARS-CoV-2 and seasonal
CCoVs25,47. Moreover, because circulating CCoVs have a higher
homology to SARS-CoV-2 structural proteins than non-structural
proteins (if they exist)48,49, we expect a higher cross-reactivity for
structural proteins based on pre-existing immunity. SARS-CoV-2
infection back-boosts antibodies against conserved epitopes,
including the relatively conserved fusion peptide of the Spike
S2 subunit25,47. In our hands, COVID-19 children and adults had
comparable levels of S2 antibodies, contrary to S1 and S2′, which
shows a possible effect of pre-existing CCoVs immunity for more
conserved domains of S such as S2. Shrock et al. used VirScan, a
DNA bacteriophage microarray, to investigate cross-reactivity
between SARS-CoV-2 and CCoV in COVID-19 patients25. They
identiﬁed cross-reactive epitopes and found that cross-reactivity
was weaker in severe patients than in mild patients, but samples
from children were not included in this study.
Our observations of lower Spike antibodies in COVID-19
children may indicate that there may be lower sensitivity of serological detection for SARS-CoV-2 when using assays based on S
alone50, leading to an underestimation of SARS-CoV-2 exposed
children. S antibodies have been reported in lower magnitude in
the majority of mild adult infections, with higher levels being
produced in severe cases51, which is consistent with our data on
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low S antibody levels in children which were also asymptomatic
or mild clinical scores. Low antibody levels and low afﬁnity have
been associated with Antibody-Dependent Enhancement by
facilitation of viral uptake by host cells52, it has now been
demonstrated that binding of antibodies to the N-terminal
domain (NTD) of S enhances infectivity53, meaning that lower
S-NTD antibody prevalence in children could be advantageous.
The combinatory use of ORF8 and ORF3d antibodies has been
shown to be a highly speciﬁc and sensitive tool for COVID-19
serology diagnostic24, and appears here as an accurate tool also
for the pediatric population. In line with our results, ORF8 has
recently been reported as an immunodominant antigenic site with
high sensitivity for the serodiagnosis of mild and severe COVID19 children54. The plane (ORF3d/ORF8) in the cluster of points
(N, ORF3d, ORF8) reveals that children samples have speciﬁc
combinatory values of these two antibodies that is consistent with
adult populations, and that makes them distinguishable from
uninfected controls. The PCA of our dataset conﬁrmed further
the importance of antibodies to accessory proteins in characterizing the pediatric samples, notably ORF3d, NSP1, ORF3a, ORF8.
Whether these antibodies to accessory proteins play a role in the
virus infectivity or in the pathogenesis of the disease and in the
milder outcome of SARS-CoV-2 infection in children presents
further questions for investigations.
We report in children diverse antibody proﬁles in early versus
late samples and the maintenance or increase of all antibodies to
structural and accessory proteins, except ORF7b antibodies, for at
least 6 months post-infection. Many factors play a role in antibody long-term persistence, such as antigen release, antigen
presentation, induction of a germinal center reaction, and a
memory B cell pool55. Additional studies on viral proteins release,
their roles, and their speciﬁc B cells are needed to fully understand the pattern of antibody speciﬁcity in children.
To complement serological data and to understand the link
between the inﬂammatory response and the distinct pattern of
antibody speciﬁcity observed in children, circulating cytokines
were measured in samples from acute time-points (<day 8). In
our hands, IL-8 and MCP-1 correlated with the overall antibody
speciﬁcity observed in our cohort, and particularly with antibodies to accessory proteins, including ORF3d and ORF8,
reﬂecting the potential role of these targets in the shaping the
adaptive host-pathogen response. These chemokines have been
identiﬁed by others as determinant in the cytokine storm
observed in COVID-19 patients40, and have been shown to
predict disease severity and outcome41. High serum levels of IL-6,
IL-8, and MCP141,56 have been correlated with poor prognosis,
hence the identiﬁcation of potential antibody associations and
levels could also inform on disease outcome and mechanisms of
viral pathogenesis. Pediatric patients have been shown to have
lower disease burden and subsequently have lower cytokine levels
compared to adults for IL-8, IL-6, and MCP-1, consistent with
previous ﬁndings41,56. Moreover, blockade of ORF8 signaling has
been shown to reduce production of hyper-inﬂammatory
cytokine57. Interestingly ORF8 antibodies correlated negatively
with IL-6, which independently predict disease severity41. Whether these antibodies can play a beneﬁcial role in reducing the
cytokine storm and the overall viral infection needs to be determined, as ORF8 has been shown to play a role in the pathogenesis
of the virus30,31.
Structural protein E correlated negatively with all cytokines
tested and has been shown to not elicit an antibody response in
COVID-19 mild adults24 but does contribute to 10.99% of the
magnitude of the pediatric antibody response pointing to the
different expression of E during pediatric infection. Indeed, E is a
TLR2 ligand for SARS-CoV-2 that can induce pro-inﬂammatory
cytokines often associated with severe COVID-1958, hence the
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potential of anti-E antibodies blocking that interaction in children
should be further investigated and potentially considered as a
therapeutic tool in severe COVID-19.
Our cohort did not include any case of the very rare MultiInﬂammatory System in Children (MIS-C). In our hands,
symptomatic (mild) children have signiﬁcant differences in
antibody levels versus symptomatic adults for antibodies to all
accessory proteins tested (excluding ORF3a) which suggests that
these accessory markers could play a role in infection control or
infectivity. One study reported that no distinct antibody response
was observed between MIS-C and mild or asymptomatic
children45, though the authors only measured S and N antibodies.
More recently, Ravichandran et al. described the SARS-CoV-2
immune repertoire in MIS-C versus mild and severe pediatric
COVID-19 cases and identiﬁed a diverse antibody-signature
associated with disease severity in children54, highlighting the
need for further studying the antibody speciﬁcity in this population to determine mechanisms for pathogenesis.
It is possible that the interest in antibodies to SARS-CoV-2
internal proteins will grow with the rollout of sub-unit Spike only
and whole inactivated virion vaccines, in order to allow the distinction between SARS-CoV-2 past infection and vaccination in
speciﬁc populations and to create an estimated date of exposure
given the unique rate of waning of different speciﬁcities. Inactivated
vaccines represent the greatest proportion of COVID-19 vaccine
doses59, and N remains an immunodominant antibody response in
CoronaVac whole inactivated virus-vaccinated individuals60. So far,
S and N-based serology have been inadequate for this18,61, and in
our hands ORF8 could distinguish between vaccinated (both Spike
mRNA and whole inactivated virus vaccines) and infected convalescent controls (Supplementary Fig. 1f). The emergence of certain viral mutants such as the ORF8 truncations31 or recent ORF3d
deletions62 could modify the contributions of certain ORFs to virus
pathogenesis and their utility as serological markers of infection in
the future. These unique antibody responses could also be useful for
epidemiology studies on the insurgence of different strains of the
virus due to higher conservation rates than surface proteins.
However, combined multivalent serology may be needed in the case
of deletion variants such as Alpha B1.1.7 for ORF8 and Beta B1.35.1
for ORF3d (reviewed in ref. 63). Furthermore, the detection of
various isotypes of antibodies for internal proteins such as IgM and
IgA could also be relevant to assess the class switching, kinetic and
Fc-related functions of the responses to non-surface proteins. Previously, a study using a SARS-CoV-2 proteome microarray enabled
the detection of IgG and IgM to a wide-range of viral proteins, and
identiﬁed alternative proteins NSP5 and ORF9b as signiﬁcant
antibody targets26.
In conclusion, we report the description of a more diversiﬁed
antibody speciﬁcity in the COVID-19 children population compared to adults, with a sustained humoral response to all accessory proteins of the virus. This study of antibody spectrum
provides insights into the importance of the breadth of antibody
responses which differs between children and adults possibly due
to differences in virus replication, expression levels, and different
immune responses in children towards key viral proteins, ORF8
and E. Our study calls for improved SARS-CoV-2 diagnostics for
the pediatric population to move beyond the spike and utilize
additional antigenic targets that trigger larger responses that
are more stable with time. This will become more important in
the near future with the up-coming roll-out of vaccines in the
pediatric population where natural infection and vaccination will
need to be distinguished.
Methods
Patients and samples collection. Our study enrolled a total of 122 children
patients and 71 adult unvaccinated patients based on recruitment of available
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patients with RT-PCR conﬁrmed COVID-19 infection in Hong Kong and in the
USA. We used a total of 254 COVID-19 children plasma samples including 146
longitudinal samples from 58 subjects with 2 to 4 sampling time points, and 119
early time-points samples (< day 14). Samples were used from children (mean ±
stdev: 39 ± 47 days, range: 0–206 days) and adults (mean ± stdev: 20 ± 23 days,
range: 0–123 days), with the sample day deﬁned as day post-symptom onset or RTPCR conﬁrmation for asymptomatic cases through contact tracing or quarantine.
The COVID-19 patient study was approved by the institutional review board of the
respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central/Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong
Kong West Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong
Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC
2020.229), and the Human Research Protection Ofﬁce at Washington University in
St. Louis, USA (IRB reference number 202007097). All of the patients provided
informed consent.
The negative control plasma samples used in this study were from Hong Kong
blood donors collected from June to August 2017 (prior to the emergence of
COVID-19), used a total of 48 plasma samples including negative pediatric samples
(n = 20) and negative adult samples (n = 28). The collection of negative control
blood donors was approved by the Institutional Review Board of The Hong Kong
University and the Hong Kong Island West Cluster of Hospitals (approval number:
UW16-254). All of the donors provided informed consent. Plasma samples were
collected from heparinized blood. All samples from COVID-19 patients or negative
controls were heat-inactivated prior to experimental use at 56 °C for 30 min. Heatinactivated and non-heat-inactivated samples were initially tested in the laboratory
and by others64,65. Details on the sample cohort are presented in Table 1.
Luciferase immunoprecipitation system (LIPS) assay. The LIPS assay is a liquid
phase immune-assay allowing the unbiased quantiﬁcation of antibodies by measuring luminescence emitted by the reporter enzyme Renilla luciferase (Ruc) fused
to an antigen of interest, expressed by the pRen2 vector in mammalian cells.
Luciferase, a light-producing enzyme is used as a reporter. The construction of
Renilla luciferase (Ruc) chimeric genes involves the mammalian expression vectors
pREN2 in which the antigen of interest is fused in-frame with Ruc. Protein A/G
beads capture the immunoglobulin-antigen complexes. Protein A/G binds predominantly to the four isotypes of IgG but can also bind, to a much lesser extent, to
IgA and IgM. Therefore, our data primarily represents plasma IgG. The use of LIPS
in the diagnostic of SARS-CoV-2 infection has been published by us and others (for
the 14 antigens tested in the present study24, for Spike and Nucleocapsid66–68).
Based on previous studies describing the structure of the SARS-CoV-2
genome49,69, an extensive panel of 14 proteins (S1, S2, S2′, E, M, N, NSP1, ORF3a,
ORF3, ORF6, ORF7a, ORF7b, ORF8, ORF10) was chosen for antibody testing by
LIPS. Primers for the ampliﬁcation of SARS-CoV-2 proteins were designed (see
protein ID and primers sequences in Supplementary Table 1). Primers and cloning
for the ampliﬁcation of SARS-CoV-2 proteins were as previously described24.
Constructs with pREN2-Renilla luciferase plasmid containing the SARS-CoV-2
antigen of interest were transfected into Cos1 cells using Fugene 6 (Promega) as per
manufacturer’s instructions. Cells were harvested 48 h later, lysed and sonicated,
and (Ruc)-antigen yields were measured using a Luminometer plate reader
(PerkinElmer) according to the protocol of Burbelo et al.64 as previously described,
with the following modiﬁcations24.
Brieﬂy, (Ruc)-antigen (at an equal concentration for each antigen at 107 per
well) and plasma (heat-inactivated and diluted 1:100) were incubated for 2 h with
shaking at 800 rpm. Ultralink protein A/G beads (Thermo-Fisher) were added to
the (Ruc)-antigen and serum mixture in a 96-deep-well polypropylene microtiter
plate and incubated for 2 h with shaking at 800 rpm. The entire volume was then
transferred into HTS plates (Millipore) and washed as previously described. The
plate was read using QUANTI-Luc Gold substrate (Invivogen) as per
manufacturer’s instructions on a Wallac MicroBeta JET luminometer 1450 LSC &
Luminescence counter and GLOMAX v1.7.1 software for analysis (Promega).
Experimental controls include no plasma blank wells with (Ruc)-antigens and
negative control serum from healthy donor plasmas collected prior to the COVID19 pandemic (Table 1). The background corresponds to the LU signal from each
Ruc-fusion antigen with protein A/G and substrate with no plasma. Responses
were considered negative when they were not signiﬁcantly elevated compared to
negative pre-pandemic controls.
Enzyme-linked immunosorbent assay. Total IgG were measured in plasma
samples using the Total humanprot IgG ELISA kit (Thermo-Fisher) at a ﬁnal
dilution of 1:500,000 according to manufacturer’s instructions.

Analysis and representation of the dataset as clusters of points. The SARSCoV-2 antibodies dataset has been analyzed through the free software ConTeXt,
with LuaMetaTeXengine (version 2020.05.18) developed by Hans Hagen (http://
www.pragma-ade.nl) which uses TeX, Metapost, and Lua to obtain the 3D clusters
of points shown in Figs. 3a–c, 7c and Supplementary Fig. 2. In the clusters of
points, each sample is represented according to 3 parameters in the 3 axes (x, y, z).
This analysis of the dataset considers a combination of three different parameters
taken together. For clarity, only the ﬁrst 144 COVID-19 pediatric samples of the
dataset are represented in the clusters of points, along with the total COVID-19
adult samples (n = 71) and negatives (n = 48).
In the cluster (N, ORF3d, ORF8), the equations of the red lines are (1) in the
plane (N, ORF8): 830*log (N) + 0.3843*ORF8 = 4801 and −350*log (N) + 1.036*
ORF8 = 790, and (2) in the plane (ORF3d, ORF8): 0.035*ORF3d + 0.1334*ORF8
= 409.284 and 0.074*ORF3d + 0.0437*ORF8 = 221.812. These straight lines allow
the most accurate discrimination between negative controls and positive adult
populations.
Principal component analysis. The LU for 14 antigens were log-scale transformed
(the negative and zero values in the dataset were replaced by 1) prior to PCA
analysis. The missing values in the dataset were estimated by a probabilistic
model70. The probabilistic model is tolerant to amounts of missing values between
10% and 15% which is ﬁt for our data. The missing data were estimated using
pcaMethods (version 1.80.0)71. The completed data were standardized (scaled)
before input in standard PCA (using FactoMineR (version 2.4)72. The PCA results
were extracted and visualized using factoextra (version 1.0.7)73.
Statistics and reproducibility. GraphPad Prism version 10 software (San Diego,
CA) was used for statistical analysis. All experiments were repeated twice independently. Antibody levels are presented as the individual responses and geometric
mean ± standard deviation (stdev). Ordinary one-way ANOVA with Tukey’s
multiple comparison test was performed to compare the pediatric, adult, and
negative populations in Figs. 1 and 2, and the early and late samples in Fig. 5. For
Fig. 2j, percentages were calculated by dividing each mean antibody value by the
sum of the total antibody responses (including or excluding N responses), and
compared using a Chi-square test between the “observed” (pediatric) versus
“expected” (adult) distributions.
For Fig. 6c and Supplementary Fig. 4, a linear mixed-effects model was ﬁtted to
account for correlated responses for the longitudinal samples dataset. Log10 LIPS
was used for the analysis (as dependent variable) to reduce the impact of extreme
values/non-normality. For Supplementary Fig. 1, the distributions showed in the
pie-charts were compared using a Chi-square test between the “observed”
(pediatric) versus “expected” (adult) distributions.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The raw data that support the ﬁndings of this study included as supplementary ﬁles, from
which PCA analysis is derived from (Fig. 3d–h, and 7b-d). Data from LIPS and ELISA
IgG responses with background subtracted are indicated in all ﬁgures are shown.
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